

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Acton, Susan L.  
Application No.: TBA Group No.: TBA  
Filed: Herewith Examiner: TBA  
For: NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (4 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
**37 C.F.R. SECTION 1.8(a)** **37 C.F.R. SECTION 1.10\***
- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV439625520US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: February 25, 2004

Sean Hunziker  
(type or print name of person certifying)

Practitioner's Docket No. **MPI98-052P1RDV10DV1M**

**Preliminary Statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted**


This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/ 757,982 , filed on January 10, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

February 25, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Tracy M. Sioussat  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 374-7679  
Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

|                        |                      |
|------------------------|----------------------|
| Application Number     | TBA                  |
| Filing Date            | Herewith             |
| First Named Inventor   | Acton, Susan L.      |
| Group Art Unit         | TBA                  |
| Examiner Name          | TBA                  |
| Attorney Docket Number | MP198-052P1RDV10DV1M |

### U.S. PATENT DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | U.S. Patent Document |                                      | Name of Patentee or Applicant<br>of Cited Document | Date of Publication of<br>Cited Document<br>(MM-DD-YYYY) | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|-----------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
|                       |                          | Number               | Kind Code <sup>2</sup><br>(if known) |  |  |   |
|                       | A1                       | 6,180,358            |                                      | Acton  | 01-2001  |   |
|                       | A2                       | 6,258,582            |                                      | Acton  | 07-2001  |   |
|                       | A3                       | 6,146,832            |                                      | Acton  | 11-2000  |   |
|                       | A4                       | 6,121,030            |                                      | Acton  | 09-2000  |   |
|                       |                          |                      |                                      |  |  |   |
|                       |                          |                      |                                      |  |  |   |
|                       |                          |                      |                                      |  |  |   |
|                       |                          |                      |                                      |  |  |   |
|                       |                          |                      |                                      |  |  |   |
|                       |                          |                      |                                      |  |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee<br>or Applicant<br>of Cited Document | Date of<br>Publication of<br>Cited Document<br>(MM-DD-YYYY) | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|-----------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|---|---|----------------|
|                       |                          | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup><br>(if known) |   |   |   |                |
|                       | B1                       | WO                      | 98/11234            | 03/98                                |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |
|                       |                          |                         |                     |                                      |   |   |   |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                      |
|---|---|----|---|--------------------------|----------------------|
| Substitute for form 1449B/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p> |   |    |   | <b>Complete if Known</b> |                      |
|   |   |    |   | Application Number       | TBA                  |
|   |   |    |   | Filing Date              | Herewith             |
|   |   |    |   | First Named Inventor     | Acton, Susan L.      |
|   |   |    |   | Group Art Unit           | TBA                  |
|   |   |    |   | Examiner Name            | TBA                  |
| Sheet   | 1 | of | 3 | Attorney Docket Number   | MPI98-052P1RDV10DV1M |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials*                                 | Cite No. <sup>1</sup> | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published. | T <sup>2</sup> |
|  | C1                    | GenBank Accession Number AA746653 for Homo Sapiens cDNA clone 1257327, January 22, 1990   |                |
|  | C2                    | GenBank Accession Number AA937590 for Homo Sapiens cDNA clone 1425841, August 24, 1998  |                |
|  | C3                    | GenBank Accession Number AA503192 for Homo Sapiens cDNA clone 956612, August 20, 1997   |                |
|  | C4                    | GenBank Accession Number B38320 for Homo Sapiens genomic clone Plate=CT 830 Col=16 Row=0, October 17, 1997  |                |
|  | C5                    | GenBank Accession Number AL023513 for Human DNA sequence from clone 268D13, September 23, 1998  |                |
|  | C6                    | GenBank Accession Number G21973 for Human STS WI-15835, May 31, 1996  |                |
|  | C8                    | GenBank Accession Number AA399022 for Soares testis-NHT Homo Sapiens cDNA clone 729929, May 16, 1997  |                |
|  | C9                    | GenBank Accession Number AA516800 for Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone 902193, July 14, 1997  |                |
|  | C10                   | GenBank Accession Number Q09298 for HYPOTHETICAL 141.2 KD PROTEIN EEED8.9, July 15, 1998  |                |
|  | C11                   | GenBank Accession Number AA307961 for Colon carcinoma (HCC) cell line II Homo Sapiens cDNA, April 18, 1997  |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                        |                      |                          |  |
|--|---|------------------------|----------------------|--------------------------|--|
| Substitute for form 1449B/PTO<br><br><h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(use as many sheets as necessary)</i></p> |   |                        |                      | <b>Complete if Known</b> |  |
|  |   | Application Number     | TBA                  |                          |  |
|  |   | Filing Date            | Herewith             |                          |  |
|  |   | First Named Inventor   | Acton, Susan L.      |                          |  |
|  |   | Group Art Unit         | TBA                  |                          |  |
|  |   | Examiner Name          | TBA                  |                          |  |
|  |   | Attorney Docket Number | MPI98-052P1RDV10DV1M |                          |  |
| Sheet  | 2 | of                     | 3                    |                          |  |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                          |   |                |  |
|--|--------------------------|---|----------------|--|
| Examiner<br>Initials*                              | Cite<br>No. <sup>1</sup> | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published. | T <sup>2</sup> |  |
|  | C12                      | GenBank Accession Number AA307684 for Colon carcinoma (HCC) cell line II Homo Sapiens cDNA, April 18, 1997  |                |  |
|  | C13                      | GenBank Accession Number AA310905 Jurkat T-cells V Homo Sapiens cDNA , April 9, 1997  |                |  |
|  | C14                      | Adams, M. D. et al., "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence," Nature 377:3-174 (1995)   |                |  |
|  | C15                      | Jurka, J. et al., "Reconstruction and Analysis of Human Alu Genes," J. Mol. Evol. 32(2):105-121 (1991)  |                |  |
|  | C16                      | Claverie, J-M. et al., "Alu Alert," Nature 371 :752 (1994)  |                |  |
|  | C17                      | Nagase, T. et al., "Prediction of the coding Sequences of Unidentified Human Genes. IX. The Complete Sequence of 100 new cDNA Clones From the Brain Which Can Code for Large Proteins in Vitro," DNA Res. 5:31-39 (1998)  |                |  |
|  | C18                      | Schultz, S. J. et al., "Identification of 21 Novel Human Protein Kinases, Including 3 Members of a Family Related to the Cell Cycle Regulator nimA of Aspergillus Nidulans," Cell Growth Differ. 4(10):821-830 (1993)   |                |  |
|  | C19                      | Schultz, S. J. et al., "Cell Cycle-Dependent Expression of Nek2, a Novel Human Protein Kinase Related to the NIMA Mitotic Regulator of Aspergillus Nidulans," Cell Growth Differ. 5(6):625-635 (1994)   |                |  |
|  | C20                      | Katoh, M. et al., "Cloning and Characterization of MST, a Novel (Putative) Serine/Threonine Kinase with SH3 Domain," Oncogene 10(7):1447-1451 (1995)  |                |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |        |                          |                      |
|--|--------|--------------------------|----------------------|
| Substitute for form 1449B/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> |        | <b>Complete if Known</b> |                      |
|  |        | Application Number       | TBA                  |
|  |        | Filing Date              | Herewith             |
|  |        | First Named Inventor     | Acton, Susan L.      |
|  |        | Group Art Unit           | TBA                  |
|  |        | Examiner Name            | TBA                  |
| Sheet  | 3 of 3 | Attorney Docket Number   | MPI98-052P1RDV10DV1M |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials*                                 | Cite No. <sup>1</sup> | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published. | T <sup>2</sup> |
|  | C21                   | Kawai T. et al., "Zip-Kinase, A Novel Serine/threonine Kinase which Mediates Apoptosis," Mol. Cell Biol. 18:1642-1651 (1998)  |                |
|  | C22                   | Dorow, D. S. et al., "Identification of a New Family of Human Epithelial Protein Kinases Containing Two Leucine/isoleucine-Zipper Domains," Eur. J. Biochem. 213(2):701-710 (1993)  |                |
|  | C23                   | Deiss, L. P. et al., "Identification of a Novel Serine/Threonine Kinase and a Novel 15-kd protein as Potential Mediators of the Gamma Interferon-Induced Cell Death," Genes Dev. 9(1):15-30 (1995)  |                |
|  | C24                   | Su, U. C. et al., "NIK is a New ste20-Related Kinase That Binds NCK and MEKK1 and activates the SAPK/JNK cascade via a Conserved Regulatory Domain," The EMBO Journal 16(6):1279-1290 (1997)  |                |
|  | C25                   | Wilson, R. et al., "2.2 Mb of Contiguous Nucleotide Sequence from Chromosome III of C. Elegans," Nature 368(6466):32-38 (1994)  |                |
|  | C26                   | Ngo, J. T. et al., "Computational complexity, protein Structure prediction, and the Levinthal Paradox in the Protein Folding Problem," Birkhauser Chapter 14:435-508 (1994)   |                |
|  |                       |   |                |
|  |                       |   |                |
|  |                       |   |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.